Company Encyclopedia
View More
name
TScan Therapeutics
TCRX.US
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors.
1.912 T
TCRX.USMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking296/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-76.44%E
    • Profit Margin-1692.96%E
    • Gross Margin-1162.01%E
  • Growth ScoreD
    • Revenue YoY-10.03%D
    • Net Profit YoY-28.12%D
    • Total Assets YoY-24.65%E
    • Net Assets YoY-37.13%E
  • Cash ScoreD
    • Cash Flow Margin-5.91%D
    • OCF YoY-10.03%D
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreC
    • Gearing Ratio45.08%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TScan reports positive outcomes from ALLOHA Phase 1 trial: Treatment arm shows HR=0.50 for relapse-free survival, HR=0.61 for overall survival.

    The group receiving treatment continues to show positive outcomes with a relapse-free survival rate at a hazard ratio of 0.50 and a p-value of 0.23. In terms of overall survival, the treatment group displayed a hazard ratio of 0.61 with a p-value of 0.52, indicating promising results.

    Unusual Whales·
    US
    TCRX
    -3.79%
    Unusual Whales·
    US
    TCRX
    -3.79%

    TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | TCRX Stock News

    TScan Therapeutics announced positive updated data from its ALLOHA™ Phase 1 trial of TSC-101 at the 67th American Society of Hematology Annual Meeting. The trial showed favorable relapse-free and overall survival rates, with TSC-101 being well-tolerated and no dose-limiting toxicities observed. The company plans to expand its heme program in 2026 and initiate a pivotal study in the second quarter of 2026. The FDA has agreed to a pivotal study design for TSC-101.

    StockTitan·
    US
    TCRX
    -3.79%
    StockTitan·
    US
    TCRX
    -3.79%

    TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026

    TScan Therapeutics announced updated data from the ALLOHA Phase 1 trial for TSC-101 in hematologic malignancies and plans for a pivotal study in 2026. A virtual KOL event will discuss two-year relapse data, a new manufacturing process, and market opportunities. Results will be presented at the 67th ASH Annual Meeting. The original content was published by TScan Therapeutics via GlobeNewswire.

    Reuters·
    US
    TCRX
    -3.79%
    Reuters·
    US
    TCRX
    -3.79%

    The Nasdaq Biotechnology Index rose over 2.1%

    The Nasdaq Biotechnology Index rose by more than 2.1%. Among the constituent stocks, Personalis rose by 16.18%, Pacific Biosciences of California rose by 14.89%, Adaptive Biotechnologies rose by 12.37%, Twist Bioscience rose by 11.66%, 10X Genomics rose by 10.02%, Cullinan Oncology LLC rose by 10.21%, and Alumis rose by 9.97%. Meanwhile, Tscan Therapeutics fell by 3.56%, Applied Therapeutics fell by 7.34%, and Zevra Therapeutics fell by 7.40%

    Wallstreetcn·
    US
    ADPT
    +3.03%
    US
    ZVRA
    +2.59%
    US
    TXG
    +0.31%
    Wallstreetcn·
    US
    ADPT
    +3.03%
    US
    ZVRA
    +2.59%
    US
    TXG
    +0.31%

    TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

    TScan Therapeutics reported quarterly earnings, beating estimates by $0.07 EPS. The company posted a ($0.28) EPS, surpassing the consensus of ($0.35). Revenue was $2.51 million, above the expected $1.98 million. Despite negative return on equity and net margin, analysts have mixed ratings, with a moderate buy consensus and a $7.20 average target price. Institutional investors hold 82.83% of shares. TScan develops TCR-T therapies for cancer treatment.

    Market Beat·
    US
    TCRX
    -3.79%
    Market Beat·
    US
    TCRX
    -3.79%
    © 2025 Longbridge｜Disclaimer